How is Aurinia Pharmaceuticals Inc.’s (NASDAQ: AUPH) stock expected to perform amid current market woes?

The price of Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) closed at $8.33 in the last session, up 5.04% from day before closing price of $7.93. In other words, the price has increased by $+0.40 from its previous closing price. On the day, 2846094 shares were traded. AUPH stock price reached its highest trading level at $8.58 during the session, while it also had its lowest trading level at $7.86.

Will You Miss Out On This Growth Stock Boom?

A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.

And this is just one of our 5 Best Growth Stocks To Own For 2023.

Sponsored

Ratios:

We take a closer look at AUPH’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 10.40 and its Current Ratio is at 11.00. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.

Upgrades & Downgrades

Oppenheimer Upgraded its Perform to Outperform on December 10, 2021, whereas the target price for the stock was revised from $33 to $31.

Insider Transactions:

An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Nov 21 when Donley Matthew Maxwell bought 10,000 shares for $4.66 per share. The transaction valued at 46,600 led to the insider holds 27,927 shares of the business.

Habig Scott Michael bought 5,000 shares of AUPH for $25,075 on Nov 09. The Chief Commercial Officer now owns 5,000 shares after completing the transaction at $5.01 per share. On Nov 07, another insider, Martin Michael Robert, who serves as the Chief Business Officer of the company, bought 30,000 shares for $5.16 each. As a result, the insider paid 154,800 and bolstered with 89,512 shares of the company.

Valuation Measures:

For the stock, the TTM Price-to-Sale (P/S) ratio is 8.74 while its Price-to-Book (P/B) ratio in mrq is 2.80.

Stock Price History:

Over the past 52 weeks, AUPH has reached a high of $20.48, while it has fallen to a 52-week low of $4.07. The 50-Day Moving Average of the stock is 5.56, while the 200-Day Moving Average is calculated to be 8.45.

Shares Statistics:

According to the various share statistics, AUPH traded on average about 3.22M shares per day over the past 3-months and 4.14M shares per day over the past 10 days. A total of 141.86M shares are outstanding, with a floating share count of 132.88M. Insiders hold about 0.10% of the company’s shares, while institutions hold 40.50% stake in the company. Shares short for AUPH as of Oct 13, 2022 were 11.94M with a Short Ratio of 7.56M, compared to 11.96M on Sep 14, 2022. Therefore, it implies a Short% of Shares Outstanding of 8.42% and a Short% of Float of 8.44%.

Earnings Estimates

The company has 7 analysts who recommend its stock at the moment. On average, analysts expect EPS of -$0.17 for the current quarter, with a high estimate of $0 and a low estimate of -$0.25, while EPS last year was -$0.39. The consensus estimate for the next quarter is -$0.15, with high estimates of -$0.01 and low estimates of -$0.23.

Analysts are recommending an EPS of between -$0.68 and -$1 for the fiscal current year, implying an average EPS of -$0.83. EPS for the following year is -$0.36, with 7 analysts recommending between -$0.12 and -$0.64.

Revenue Estimates

According to 8 analysts, the current quarter’s revenue is expected to be $36.18M. It ranges from a high estimate of $62.53M to a low estimate of $29.43M. As of the current estimate, Aurinia Pharmaceuticals Inc.’s year-ago sales were $14.67M, an estimated increase of 146.70% from the year-ago figure. For the next quarter, 8 analysts are estimating revenue of $49.01M, an increase of 109.40% less than the figure of $146.70% in the same quarter last year. There is a high estimate of $72.3M for the next quarter, whereas the lowest estimate is $33.44M.

A total of 8 analysts have provided revenue estimates for AUPH’s current fiscal year. The highest revenue estimate was $156M, while the lowest revenue estimate was $112.07M, resulting in an average revenue estimate of $136.21M. In the same quarter a year ago, actual revenue was $45.6M, up 198.70% from the average estimate. Based on 8 analysts’ estimates, the company’s revenue will be $231.36M in the next fiscal year. The high estimate is $310.5M and the low estimate is $164.4M. The average revenue growth estimate for next year is up 69.90% from the average revenue estimate for this year.